ClaritevCTEV +1.43%57 EBITDA Margin % is 48.42% as of Mar. 2026, which is 17% below its 10-year median of 58.11. GuruFocus rates CTEV with a GF Score™ of 57/100 and a GF Value™ of $31.33 (Fairly Valued). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Claritev ranks better than 97.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Claritev's EBITDA for the
three
months ended in Mar. 2026 was $118.5 Mil. Claritev's Revenue for the
three
months ended in Mar. 2026 was $244.7 Mil. Therefore, Claritev's EBITDA margin for the quarter that ended in Mar. 2026 was 48.42%.
Claritev (NYSE:CTEV) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Claritev EBITDA Margin % Related Terms
Claritev EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Claritev's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTEV vs NRC, EVH, TBRG: EBITDA Margin % Comparison
For the Health Information Services subindustry, Claritev's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Claritev EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Claritev's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Claritev's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Claritev (CTEV) has a EBITDA Margin % of 48.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Claritev and its competitors. This is 17% below median its historical median of 58.11. According to the industry distribution chart, Claritev ranks #15 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 2.2%.
Is Claritev's EBITDA Margin % too high?
Claritev's current EBITDA Margin % of 48.42% is 17% below median its 10-year median of 58.11. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Claritev's value of 48.42% is 374.2% above this industry median. Based on the distribution chart, Claritev ranks #15 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Claritev has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Claritev's EBITDA Margin % compare to NRC and EVH?
According to the Healthcare Providers & Services industry distribution chart, Claritev ranks #15 out of 668 companies for EBITDA Margin %. This places Claritev in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Claritev's value of 48.42% is 374.2% above this benchmark. While the company's 10-year median is 58.11 vs. the industry median of 10.21, Claritev has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Claritev's current EBITDA Margin % of 48.42% is 374.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Claritev and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Claritev's current EBITDA Margin % is 48.42%, which is 17% below median its own 10-year median of 58.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Claritev stock overvalued right now?
Based on GuruFocus' analysis, Claritev (CTEV) is currently considered Fairly Valued. The stock's GF Value™ is $31.33, compared to a current price of $30.49 — trading 2.7% below its estimated fair value. The current EBITDA Margin % is 48.42%, which is 17% below median its 10-year median of 58.11 and 374.2% above the Healthcare Providers & Services industry median of 10.21. Claritev's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Claritev (CTEV), the current EBITDA Margin % is 48.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Claritev (CTEV) Overvalued in 2026?
Based on GuruFocus' analysis, Claritev stock appears to be undervalued.
The current stock price of $30.49 is trading 2.7% below its estimated GF Value™ of $31.33.
GuruFocus considers Claritev to be Fairly Valued.
Key valuation signals for CTEV:
EBITDA Margin %: 48.42% (17% below median its 10-year median of 58.11)
GF Value™: $31.33 vs. price of $30.49 (2.7% below fair value)
Industry Position: 374.2% above the Healthcare Providers & Services median (#15 of 668)
No single metric tells the full story. See the CTEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The company's focus is on being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
57GF Score
Get the complete analysis for CTEV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTEV has been successfully added to your 
